Intravenous or oral vinorelbine plus capecitabine as first-line treatment in her2 metastatic breast cancer: Joint analysis of 2 consecutive prospective phase ii trials

Clinical Breast Cancer

Volumn 12, Issue 1, 2012, Pages 30-39

  Strada, Maria Rosa ^a   Palumbo, Raffaella ^a   Bernardo, Antonio ^a   Riccardi, Alberto ^a   Teragni, Cristina ^a   Poggi, Guido ^a   Frascaroli, Mara ^a   Amatu, Alessio ^a   Montagna, Benedetta ^a   Sottotetti, Federico ^a   Tagliaferri, Barbara ^a   Bernardo, Giovanni ^a  

^a IRCCS   (Italy)

Author keywords

Capecitabine; Metastatic breast cancer; Oral chemotherapy; Vinorelbine

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY IMAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEXUAL FUNCTION; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 84856031837     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.11.001     Document Type: Article

References (55)

1. V. Guarneri, P.F. Conte The curability of breast cancer and the treatment of advanced disease Eur J Nucl Med Mol Imaging 31 suppl 1 2004 S14 S161
2. J.R. Gralow Optimizing the treatment of metastatic breast cancer Breast Cancer Res Treat 89 suppl 1 2005 S9 S15
3. I. Smith Goals of treatment for patients with metastatic breast cancer Semin Oncol 33 1 suppl 2 2006 S2 S5
4. F.J. Estava, V. Valero, L. Pustal Strategies of medical treatment for metastatic breast cancer: what is expected in 2001 and beyond Oncologist 6 2001 133 136
5. A.D. Seidman Systemic treatment of breast cancer Two decades of progress Oncology (Williston Park) 20 2006 983 990 (Pubitemid 46940825)
6. National Comprehensive Cancer Network NCCN guidelines 2008 http://www.nccn.org/professionals/physicia-gls/pdf/breast.pdf
7. D. Mauri, N. Polyzos, G. Salanti Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer J Natl Cancer Inst 100 2008 1780 1791
8. M.L. Telli, R.W. Carlson First-line chemotherapy for metastatic breast cancer Clin Breast Cancer 9 suppl 2 2009 S66 S72
9. D.W. Miles When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer Breast Cancer Res 11 2009 208 219
10. C. Andreetta, M.A. Minisini, M. Miscoria First-line chemotherapy with or without biologic agents for metastatic breast cancer Crit Rev Oncol Hematol 76 2010 99 111
11. N. Wilcken, R. Dear Chemotherapy in metastatic breast cancer: a summary of all randomized trials reported 2000-2007 Eur J Cancer 44 2008 2218 2225
12. F. Cardoso, P.L. Bedard, E.P. Winer International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy J Natl Cancer Inst 101 2009 1174 1181
13. V. Guarneri, P.F. Conte Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy Oncologist 14 2009 645 656
14. M. Mano Vinorelbine in the management of breast cancer: new perspectives, revised role in the era of targeted therapy Cancer Treat Rev 32 2006 106 118 (Pubitemid 43362232)
15. P. Barrett-Lee, F.C. Bidard, J.Y. Pierga Contemporary issues and the potential uses of capecitabine in metastatic breast cancer Cancer Treat Rev 35 2009 582 589
16. V. Lorusso, E. Crucitta, N. Silvestri A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer Clin Breast Cancer 4 2003 138 141 (Pubitemid 36939420)
17. N. Stuart, J.L. Bishop, S.R.D. Johnson Vinorelbine and capecitabine (VX) for advanced breast cancer: a phase II study showing good activity and potential for further development Proc Am Soc Clin Oncol 22 2003 abstract 183 www.asco.org Accessed: November 11, 2011
18. J.H. Ahn, S.B. Kim, T.W. Kim Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane J Korean Med Sci 19 2004 547 552
19. A. Welt, G. Minckwitz, C. Oberhoff Phase I-II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer Ann Oncol 16 2005 64 69 (Pubitemid 40124480)
20. M. Ghosn, J. Kattan, F. Farhat Phase I trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients Anticancer Res 26 2006 2451 2456 (Pubitemid 43980216)
21. F. Nol, C. Catania, M. Munzone Capecitabine/vinorelbine: an effective and well tolerated regimen for women with pretreated advanced breast cancer Clin Breast Cancer 6 2006 518 524
22. D. Hess, D. Koberle, B. Thurlimann Capecitabine and vinorelbine as first-line treatment in elderly patients (> or = 65 years) with metastatic breast cancer A phase II trial (SAKK 25/99) Oncology 73 2007 228 237 (Pubitemid 351630055)
23. L. Favier, N. Isambert, S. Zanetta Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer Breast 17 2008 38 43
24. G.L. Estvez, N. Batista, P. Snchez-Rovira A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes Clin Breast Cancer 8 2008 149 154 (Pubitemid 351655929)
25. B. Pajk, T. Cufer, P. Canney Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase I trial Breast 17 2008 180 185 (Pubitemid 351467955)
26. R. Palumbo, A. Bernardo, M.R. Strada Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer Eur J Cancer 67 suppl 2008 177 abstract 425
27. M. Marty, P. Fumoleau, A. Adenis Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors Ann Oncol 12 2001 1643 1649 (Pubitemid 34070598)
28. P. Variol, L. Nguyen, B. Tranchard A simultaneous oral/intravenous population pharmacokinetics model for vinorelbine Eur J Clin Pharmacol 58 2002 467 476 (Pubitemid 35244920)
29. T. De Pas, A. Sbanotto, C. Catania Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain Support Care Cancer 13 2005 194 195 (Pubitemid 40468967)
30. H. Bourgeois, J. Vermorken, G. Dark Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours Cancer Chemother Pharmacol 60 2007 407 413 (Pubitemid 46944594)
31. R. Addeo, A. Sgambato, G. Cennamo Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer Clin Breast Cancer 10 2010 301 306
32. G. Freyer, T. Delozier, A.M. Lichinister A phase II study of oral vinorelbine (NVBo) in first line locally advanced/metastatic breast cancer (ABC) chemotherapy J Clin Oncol 21 2003 35 40
33. V. Trillet-Lenoir, H. Sommer, T. Delozier Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II trials Eur J Cancer 2 2004 137 (abstract 279)
34. M. Baweja, V.J. Suman, T.R. Fitch Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients <65 years of age: an NCCTG study Ann Oncol 17 2006 623 629
35. P. Kellokumpu-Lehtinen, K. Sunela, I. Lehtinen A phase I study of an all oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxances Clin Breast Cancer 7 2006 401 405 (Pubitemid 46157561)
36. F. Nol, C. Catania, G. Sanna Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer Ann Oncol 17 2006 322 329 (Pubitemid 43160124)
37. A. Anton, A. Lluch, A. Casado Phase I-II study of oral vinorelbine and capecitabine in metastatic breast cancer: results of the phase I trial J Clin Oncol 26 2008 abstract 1105 www.asco.org Accessed: November 11, 2011
38. T.R. Fleming One sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
39. A.B. Miller, B.B. Hoogstraten, M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214 (Pubitemid 11167383)
40. E.L. Kaplan, P. Meier Non parametric estimation from incomplete observation J Am Stat Assoc 53 1958 457 481
41. M.A. Sprangers, M. Groenvold, J.I. Arraras The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study J Clin Oncol 14 1996 2756 2768 (Pubitemid 26329662)
42. A. Coates, M. Stockler, N. Wilcken Controversies in Metastatic Breast Cancer: Optimal Duration of Chemotherapy ASCO Educational Book 2003 American Society of Clinical Oncology Alexandria, VA 119 121
43. A. Gennari, M. Sormani, P. Bruzzi A meta-analysis of chemotherapy duration in metastatic breast cancer J Clin Oncol 26 2008 abstract 1067,2008 www.asco.org Accessed: November 11, 2011
44. E. Liu, E. Franssen, M.I. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115 (Pubitemid 27021524)
45. C. Catania, F. Didier, M.E. Leon Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer Breast Cancer Res Treat 92 2005 265 272 (Pubitemid 41279636)
46. L. Fallowfield, L. Atkins, S. Catt Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer Ann Oncol 17 2006 205 210 (Pubitemid 43160107)
47. M. Findlay, G. von Minckwitz, A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann Oncol 19 2008 212 222 (Pubitemid 351201700)
48. A. Chan, M. Verril Capecitabine and vinorelbine in metastatic breast cancer Eur J Cancer 45 2009 2253 2265
49. C. Delcambre, L. Veyret, C. Levy A phase I/II study of capecitabine combined with oral vinorelbine as first- or second-line therapy in locally advanced or metastatic breast cancer Breast Cancer Res Treat 94 suppl 1 2005 1081
50. Lorusso V, Spada M, Giampaglia M, et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 17(suppl 1):VII15-17.
51. J. Finek, I. Holubec Jr, T. Svoboda A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer Anticancer Res 29 2009 667 670
52. F. Nol, D. Crivellari, R. Mattioli Phase II study of an all oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer Cancer Chemother Pharmacol 64 2009 673 680
53. N. Tubiana-Mathieu, P. Bougnoux, D. Becquart All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial Br J Cancer 101 2009 232 237
54. A. Chan, V. Ganju, D. Becquart High efficacy of the combination of oral vinorelbine (NVBo) and capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months Eur J Cancer 7 2009 277 (abstract 5055)
55. R. Palumbo, A. Bernardo, M.R. Strada Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well tolerated regimen that allows patient compliance Eur J Cancer 7 2009 285 (abstract 5081)